Blood test “clocks” predict when Alzheimer’s symptoms will start

WashU Medicine researchers developed a model to estimate when Alzheimer’s disease symptoms will begin based on the accumulation of amyloid and tau proteins in the brain. These proteins build up predictably over time, like tree rings, providing scientists with a clock for Alzheimer’s symptoms.

Researchers at Washington University School of Medicine in St. Louis have developed a method to predict when someone is likely to develop symptoms of Alzheimer’s disease using a single blood test.

In a new study published Feb. 19 in Nature Medicine, the researchers demonstrated that their models predicted the onset of Alzheimer’s symptoms within a margin of three to four years. This could have implications both for clinical trials developing preventive Alzheimer’s treatments and for eventually identifying individuals likely to benefit from these treatments.

Study of 27.8M Americans May Have Revealed Direct Alzheimer’s Cause

Scientists have just found a direct link between air pollution and Alzheimer’s disease—suggesting that improving air quality could be an important way to prevent dementia and protect older adults. 

Alzheimer’s disease is the most common form of dementia, which affects about 57 million people worldwide, and there is currently no cure for it, making prevention is crucial. 

Read more about this study HERE

Scientists discover brain switches that clear Alzheimer’s plaques

Researchers have identified two brain receptors that help the brain clear away amyloid beta, a hallmark of Alzheimer’s disease. By stimulating these receptors in mice, scientists increased levels of a natural amyloid-breaking enzyme, reduced buildup in the brain, and improved memory-related behavior. Because these receptors are common drug targets, the findings could open the door to affordable pill-based treatments with fewer side effects.

Read more HERE

Tiny Clots Could Be the Missing Piece in Alzheimer’s Puzzle

Researchers have long recognized that Alzheimer’s disease is marked by abnormal plaques and tangled proteins in the brain. More recently, attention has turned to the brain’s blood vessels and how problems in the vascular system may influence the course of the disease. Even with decades of discoveries, however, these insights have not yet led to treatments that fully stop or reverse Alzheimer’s. A major reason is that scientists still do not have a complete picture of how brain cells progressively break down over time.

Read more HERE

AI uncovers the hidden genetic control centers driving Alzheimer’s

Scientists have created the most detailed maps yet of how genes control one another inside the brains of people with Alzheimer’s disease. Using a powerful new AI-based system called SIGNET, the team uncovered cause-and-effect relationships between genes across six major brain cell types, revealing which genes are truly driving harmful changes. The most dramatic disruptions were found in excitatory neurons, where thousands of genetic interactions appear to be extensively rewired as the disease progresses.

Read more about it HERE

The Creation Of An Alzheimer’s Detection Test

THE U.S. IS in a dementia crisis. According to a recent study published in Nature Medicine, by 2060, diagnoses of cognitive decline are expected to hit a rate of 1 million a year—double what they were in 2020. That’s one of the reasons the FDA’s approval of a new test from local drug company Eli Lilly and Swiss medication company Roche is such a big deal. Developed with help from scientists at the Indiana University School of Medicine, the test, called the Elecsys pTau181, uses blood-based biomarkers to determine the likelihood that someone with dementia symptoms has Alzheimer’s disease or if they’re suffering from another disorder.

Read more HERE